Molecular therapy in pancreatic adenocarcinoma

Lancet Oncol. 2004 Sep;5(9):541-9. doi: 10.1016/S1470-2045(04)01565-7.

Abstract

Pancreatic cancer is one of the commonest causes of death from cancer. Despite therapy with surgery, conventional chemotherapy, and radiation, 5-year survival for patients with this diagnosis remains poor. However, advances in the molecular understanding of this malignant disease over the past 5 years might lead to new treatment strategies. Strategies of gene therapy, antiangiogenic treatments, immunotherapy, and signal-transduction inhibition are in preclinical development. This review presents an overview of molecular therapy in pancreatic cancer.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / therapy*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Clinical Trials as Topic
  • Genetic Therapy / methods
  • Humans
  • Immunotherapy
  • Pancreatic Neoplasms / therapy*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal